Eli Lilly Stock Pops on Drug Efficacy for Sleep Apnea

LLY sports a whopping 106.1% year-over-year lead

Digital Content Manager
Apr 17, 2024 at 10:40 AM
facebook X logo linkedin

Eli Lilly And Co (NYSE:LLY) stock was last seen up 2.8% at $767.65, after the pharmaceutical giant said data from two late-stage trials showed its weight loss drug Zepbound helped reduce irregular breathing in patients with obstructive sleep apnea.

The security is on track to snap a four-day losing streak, and sports a whopping 106.1% year-over-year lead. Shares notched a March 4, all-time high of $800.78, with support from the $730 level, which has acted as a floor since early February.

Short-term options traders are already overwhelmingly bullish. In fact, Eli Lilly stock's Schaeffer's put/call open interest ratio (SOIR) of 0.62 ranks in the low 9th percentile of annual readings. 

Options volume is today running at double the intraday average, with 10,000 calls and 6,250 puts across the tape so far. The most active contract is the April 750 put, but the 470 call in that series is not too far behind in terms of popularity, both of which expire later this week.  


Unlock Weekend Profits with Chris Prybal's Favorite Strategy Up +487.5% in 2024

With the markets going left, right, and sideways, you need to have a plan now more than ever. 

Expert Trader Chris Prybal is no stranger to volatility, and has mastered finding big stock rallies while other traders aren't looking over the weekend. Rallies that produced gains like +207% on RTX calls, +236% on MARA calls, and +238% on NET calls.

A few simple moves on Sunday at 7pm could be the “Secret Sauce” your portfolio needs to not just stay afloat, but make unprecedented gains in this turbulent market.

Don’t sit on the sidelines, beat the market with Chris Prybal's strategy. Join him now!




Rainmaker Ads CGI